LILLY's TWICE-DAILY KEFTAB WILL BE AVAILABLE AT RETAIL BY MID-NOVEMBER
Executive Summary
LILLY's TWICE-DAILY KEFTAB WILL BE AVAILABLE AT RETAIL BY MID-NOVEMBER; Lilly announced FDA approval of the new cephalexin salt on Oct. 30. Available in 250 mg and 500 mg tablets, Keftab "can be prescribed in 500 mg doses, twice daily, to treat many bacterial infections," Lilly said in its Oct. 30 announcement. The "usual" adult dose of Lilly's Keflex (cephalexin) is 250 mg q.i.d., according to Keflex labeling. Lilly said Keftab would reach pharmacy shelves in the next "two to three weeks." Keftab pricing may cannibalize some sales from Keflex, which is already beleaguered by generic competition. Lilly said it is pricing Keftab to wholesalers at a 10% discount to Keflex. Lilly's patent for Keflex expired in April, and a number of generic cephalexin products have since reached the market. While Keftab is chemically related to Keflex, Lilly said that it is protected by a separate patent and that "a separate NDA was filed with the FDA for the compound." Keftab carries the same indications as Keflex with the exception of otitis media, Lilly said. Keftab also has no pediatric dosage form.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth